Mirabelli Christopher

SEC source: 0001104659-26-036804 · tm2610113-1_4seq1.xml · nonDerivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,376

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the previously reported settlement of RSUs on March 13, 2026.

SEC source: 0001104659-26-029645 · tm269084-9_4seq1.xml · derivative · entry 4

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 94,050 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock.

F4 · derivative.exercise_date: The December 2025 RSUs vested at issuance on their grant date.

F4 · derivative.expiration_date: The December 2025 RSUs vested at issuance on their grant date.

SEC source: 0001104659-26-029645 · tm269084-9_4seq1.xml · derivative · entry 3

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 74,700 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2016 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock").

F3 · derivative.exercise_date: The November 2025 RSUs vested at issuance on their grant date.

F3 · derivative.expiration_date: The November 2025 RSUs vested at issuance on their grant date.

SEC source: 0001104659-26-029645 · tm269084-9_4seq1.xml · nonDerivative · entry 2

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,376

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock.

F2 · price: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock.

SEC source: 0001104659-26-029645 · tm269084-9_4seq1.xml · nonDerivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,326

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2016 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock").

F1 · price: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2016 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock").

SEC source: 0001104659-25-125252 · tm2534450-3_4seq1.xml · derivative · entry 3

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,050

Underlying: Common Stock · 94,050 shares

Expires not disclosed

F4 · derivative.exercise_price: Represents restricted stock units ("RSUs") to be settled on a 1 for 1 basis for shares of Company Common Stock. The RSUs were awarded pursuant to the Company's 2025 Equity Incentive Plan for no consideration.

F5 · derivative.exercise_date: The RSUs vested at issuance on December 23, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date.

F5 · derivative.expiration_date: The RSUs vested at issuance on December 23, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date.

SEC source: 0001104659-25-125252 · tm2534450-3_4seq1.xml · nonDerivative · entry 2

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,626

F1 · kind: Pro rata distribution from Nine Capital Partners, LLC ("Nine Capital Partners") of an aggregate of 2,136 shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"), with 712 shares of Common Stock distributed to each of Messrs. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor, respectively. Messrs. Mirabelli, Onsi and Lawlor are the Managing Members of Nine Capital Partners and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC.

F3 · shares: Reflects a de minimis adjustment due to rounding.

F1 · price: Pro rata distribution from Nine Capital Partners, LLC ("Nine Capital Partners") of an aggregate of 2,136 shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"), with 712 shares of Common Stock distributed to each of Messrs. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor, respectively. Messrs. Mirabelli, Onsi and Lawlor are the Managing Members of Nine Capital Partners and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC.

SEC source: 0001104659-25-125252 · tm2534450-3_4seq1.xml · nonDerivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

F1 · kind: Pro rata distribution from Nine Capital Partners, LLC ("Nine Capital Partners") of an aggregate of 2,136 shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"), with 712 shares of Common Stock distributed to each of Messrs. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor, respectively. Messrs. Mirabelli, Onsi and Lawlor are the Managing Members of Nine Capital Partners and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC.

F1 · shares: Pro rata distribution from Nine Capital Partners, LLC ("Nine Capital Partners") of an aggregate of 2,136 shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"), with 712 shares of Common Stock distributed to each of Messrs. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor, respectively. Messrs. Mirabelli, Onsi and Lawlor are the Managing Members of Nine Capital Partners and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC.

F1 · price: Pro rata distribution from Nine Capital Partners, LLC ("Nine Capital Partners") of an aggregate of 2,136 shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"), with 712 shares of Common Stock distributed to each of Messrs. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor, respectively. Messrs. Mirabelli, Onsi and Lawlor are the Managing Members of Nine Capital Partners and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC.

F1 · balance_after: Pro rata distribution from Nine Capital Partners, LLC ("Nine Capital Partners") of an aggregate of 2,136 shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"), with 712 shares of Common Stock distributed to each of Messrs. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor, respectively. Messrs. Mirabelli, Onsi and Lawlor are the Managing Members of Nine Capital Partners and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC.

F1 · ownership.nature: Pro rata distribution from Nine Capital Partners, LLC ("Nine Capital Partners") of an aggregate of 2,136 shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"), with 712 shares of Common Stock distributed to each of Messrs. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor, respectively. Messrs. Mirabelli, Onsi and Lawlor are the Managing Members of Nine Capital Partners and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC.

F2 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001104659-25-114094 · tm2531740-3_4seq1.xml · nonDerivative · entry 2

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,136

F2 · shares: On November 17, 2025, HealthCare Ventures IX, L.P. ("HCV IX") sold 414,479 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.

F3 · shares: Reflects a de minimis adjustment of one (1) share due to rounding.

F2 · price: On November 17, 2025, HealthCare Ventures IX, L.P. ("HCV IX") sold 414,479 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.

F2 · balance_after: On November 17, 2025, HealthCare Ventures IX, L.P. ("HCV IX") sold 414,479 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.

F3 · balance_after: Reflects a de minimis adjustment of one (1) share due to rounding.

F2 · ownership.nature: On November 17, 2025, HealthCare Ventures IX, L.P. ("HCV IX") sold 414,479 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.

F3 · ownership.nature: Reflects a de minimis adjustment of one (1) share due to rounding.

F4 · ownership.nature: The reporting person is a managing member of Nine Capital Partners and may be deemed to have beneficial ownership of such 2,136 shares of common stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have had beneficial ownership of the 414,479 shares of Common Stock sold by HCV IX. The reporting person is a beneficiary of the HCV Liquidating Trust and may be deemed to have had beneficial ownership of the 261,840 shares of Common Stock sold by the HCV Liquidating Trust. The reporting person disclaims beneficial ownership of such shares of common stock held by Nine Capital Partners, and sold by each of HCV IX and the HCV Liquidating Trust, except to the extent of the reporting person's proportionate pecuniary interest therein.

SEC source: 0001104659-25-114094 · tm2531740-3_4seq1.xml · nonDerivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 416,616

F1 · shares: On November 17, 2025, HCV VIII Liquidating Trust ("HCV Liquidating Trust") sold 261,840 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.

F1 · price: On November 17, 2025, HCV VIII Liquidating Trust ("HCV Liquidating Trust") sold 261,840 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.

F1 · balance_after: On November 17, 2025, HCV VIII Liquidating Trust ("HCV Liquidating Trust") sold 261,840 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.

F1 · ownership.nature: On November 17, 2025, HCV VIII Liquidating Trust ("HCV Liquidating Trust") sold 261,840 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.

F2 · ownership.nature: On November 17, 2025, HealthCare Ventures IX, L.P. ("HCV IX") sold 414,479 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.

F4 · ownership.nature: The reporting person is a managing member of Nine Capital Partners and may be deemed to have beneficial ownership of such 2,136 shares of common stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have had beneficial ownership of the 414,479 shares of Common Stock sold by HCV IX. The reporting person is a beneficiary of the HCV Liquidating Trust and may be deemed to have had beneficial ownership of the 261,840 shares of Common Stock sold by the HCV Liquidating Trust. The reporting person disclaims beneficial ownership of such shares of common stock held by Nine Capital Partners, and sold by each of HCV IX and the HCV Liquidating Trust, except to the extent of the reporting person's proportionate pecuniary interest therein.

SEC source: 0001104659-25-111434 · tm2531210-4_4seq1.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,700

Underlying: Common Stock · 74,700 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") to be settled on a 1 for 1 basis for shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"). The RSUs were awarded pursuant to the Company's 2016 Equity Incentive Plan for no consideration.

F2 · derivative.exercise_date: The RSUs vested at issuance on November 11, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date.

F2 · derivative.expiration_date: The RSUs vested at issuance on November 11, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date.

SEC source: 0001104659-25-030805 · tm2511110-5_4seq1.xml · derivative · entry 4

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,828 of such shares and the Company withheld on such settlement date the remaining 6,672 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,672 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F6 · derivative.exercise_date: The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date.

F7 · derivative.exercise_date: The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 on a net issue basis as further described on note (2) above.

F8 · derivative.expiration_date: The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs.

SEC source: 0001104659-25-030805 · tm2511110-5_4seq1.xml · nonDerivative · entry 2

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,914

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,828 of such shares and the Company withheld on such settlement date the remaining 6,672 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,672 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-25-030805 · tm2511110-5_4seq1.xml · nonDerivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,586

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,828 of such shares and the Company withheld on such settlement date the remaining 6,672 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,672 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F3 · price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-24-119791 · tm2428586-1_4seq1.xml · derivative · entry 3

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value per share · 2,136 shares

Expires 2024-11-14

F1 · kind: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

F1 · ownership.nature: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

SEC source: 0001104659-24-119791 · tm2428586-1_4seq1.xml · nonDerivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 678,456

F1 · kind: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

F2 · balance_after: Includes (i) 2,136 shares of Common Stock held by Nine Capital Partners, (ii) 414,480 shares of Common Stock held by HealthCare Ventures IX, L.P. ("HCV IX"), and (iii) 261,840 shares of Common Stock held by the HCV VIII Trust ("HCV Trust"). See footnote (1) above for an explanation of the reporting person's beneficial ownership of the 2,136 shares of Common Stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have beneficial ownership of the 414,480 shares of Common Stock held by HCV IX. The reporting person is a beneficiary of the HCV Trust and may be deemed to have beneficial ownership of the 261,840 shares of Common Stock held by the HCV Trust.

F3 · balance_after: The reporting person disclaims beneficial ownership of such shares of Common Stock held by each of Nine Capital Partners, HCV IX, and the HCV Trust, except to the extent of the reporting person's proportionate pecuniary interest in such shares of Common Stock.

F1 · ownership.nature: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

F2 · ownership.nature: Includes (i) 2,136 shares of Common Stock held by Nine Capital Partners, (ii) 414,480 shares of Common Stock held by HealthCare Ventures IX, L.P. ("HCV IX"), and (iii) 261,840 shares of Common Stock held by the HCV VIII Trust ("HCV Trust"). See footnote (1) above for an explanation of the reporting person's beneficial ownership of the 2,136 shares of Common Stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have beneficial ownership of the 414,480 shares of Common Stock held by HCV IX. The reporting person is a beneficiary of the HCV Trust and may be deemed to have beneficial ownership of the 261,840 shares of Common Stock held by the HCV Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of such shares of Common Stock held by each of Nine Capital Partners, HCV IX, and the HCV Trust, except to the extent of the reporting person's proportionate pecuniary interest in such shares of Common Stock.

SEC source: 0001104659-24-106331 · tm2425653-9_4seq1.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of October 2, 2024.

SEC source: 0001104659-24-009020 · tm244775-2_4seq1.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-01-29

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of January 29, 2024.

SEC source: 0001104659-24-008421 · tm244628-5_4seq1.xml · derivative · entry 3

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 5,000 Restricted Stock Units, vesting on January 26, 2024 or upon a change of control, whichever is earlier, provided that the grantee continues to be employed by, or provides service to the Company from the grant date to the vesting date of the Restricted Stock Units. At such time as the Restricted Stock Units vest, one share of Common Stock shall be issued automatically in settlement of each Restricted Stock Unit.

F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 5,000 Restricted Stock Units, vesting on January 26, 2024 or upon a change of control, whichever is earlier, provided that the grantee continues to be employed by, or provides service to the Company from the grant date to the vesting date of the Restricted Stock Units. At such time as the Restricted Stock Units vest, one share of Common Stock shall be issued automatically in settlement of each Restricted Stock Unit.

SEC source: 0001104659-24-008421 · tm244628-5_4seq1.xml · nonDerivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,086

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted Stock Units convert into common stock on a one-for-one basis.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-23-095364 · tm2324823-10_4seq1.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2033-08-23

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on September 23, 2023 and an additional of such monthly installments vesting on the 23rd day of each calendar month thereafter.

SEC source: 0001104659-23-041755 · tm2311741-12_4seq1.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2033-03-31

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of March 31, 2023, the Vesting Start Date.

SEC source: 0001104659-22-097618 · tm2225099-7_4seq1.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2032-08-31

F1 · derivative.exercise_date: The Option was awarded pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of September 1, 2022, the Vesting Start Date.

SEC source: 0001104659-22-011052 · tm225302-2_4seq1.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · 10% owner · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires not disclosed

F1 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock.

F1 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock.

F2 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier.

F2 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier.

SEC source: 0001104659-21-074444 · tm2117938-1_4seq1.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-05-25

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of May 26, 2021, the Vesting Start Date.

SEC source: 0001104659-21-021030 · tm216410-4_4seq1.xml · derivative · entry 2

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 11,544

Underlying: Common Stock, $0.001 par value per share · 11,544 shares

Expires 2026-02-05

F1 · kind: On February 9, 2020, HealthCare Ventures IX, L.P. ("HCVIX") transferred, for no consideration, all 571,428 warrants to purchase common stock it held (the "Transfer") to the limited partners of HCVIX on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P. ("HCPIX"), the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX.

F4 · kind: These warrants were acquired by Nine Capital Partners, LLC ("Nine Capital Partners"), a limited partner of HCVIX, in connection with the Transfer. The reporting person is a member of Nine Capital Partners and may be deemed to indirectly beneficially own and share voting and dispositive power with respect to all securities held by Nine Capital Partners. The reporting person disclaims beneficial ownership of the warrants except to the extent of his proportionate pecuniary interest therein.

F3 · price: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by HCVIX on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer.

F4 · ownership.direct: These warrants were acquired by Nine Capital Partners, LLC ("Nine Capital Partners"), a limited partner of HCVIX, in connection with the Transfer. The reporting person is a member of Nine Capital Partners and may be deemed to indirectly beneficially own and share voting and dispositive power with respect to all securities held by Nine Capital Partners. The reporting person disclaims beneficial ownership of the warrants except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001104659-21-021030 · tm216410-4_4seq1.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value per share · 571,428 shares

Expires 2026-02-05

F1 · kind: On February 9, 2020, HealthCare Ventures IX, L.P. ("HCVIX") transferred, for no consideration, all 571,428 warrants to purchase common stock it held (the "Transfer") to the limited partners of HCVIX on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P. ("HCPIX"), the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX.

F2 · kind: These warrants were owned directly by HCVIX. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HCPIX, which is the General Partner of HCVIX. Each of the HCVIX Directors, HCPIX LLC and HCPIX indirectly beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HCVIX, and each disclaimed beneficial ownership of the warrants except to the extent of his or its proportionate pecuniary interest therein.

F3 · price: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by HCVIX on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer.

F2 · ownership.direct: These warrants were owned directly by HCVIX. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HCPIX, which is the General Partner of HCVIX. Each of the HCVIX Directors, HCPIX LLC and HCPIX indirectly beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HCVIX, and each disclaimed beneficial ownership of the warrants except to the extent of his or its proportionate pecuniary interest therein.

SEC source: 0001104659-21-008999 · tm214605-2_4seq1.xml · derivative · entry 2

Mirabelli Christopher · CIK 0001262326 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires not disclosed

F2 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock.

F2 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock.

F3 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier.

F3 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier.

SEC source: 0001104659-21-008999 · tm214605-2_4seq1.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2031-01-25

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of January 26, 2021, the Vesting Start Date.

SEC source: 0001104659-20-094192 · a4.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2030-08-09

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of August 10, 2020, the Vesting Start Date.

SEC source: 0001104659-20-046073 · a4.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-04-09

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of April 9, 2020, the Vesting Start Date.

SEC source: 0001104659-19-035073 · a4.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · Pres., CEO & Chairman of Board · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2029-06-10

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of June 11, 2019, the Vesting Start Date.

SEC source: 0001104659-19-005836 · a4.xml · derivative · entry 4

Mirabelli Christopher · CIK 0001262326 · Director · CEO, President, Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 592,797

Underlying: Common Stock, $0.001 par value per share · 571,428 shares

Expires 2026-02-05

F4 · price: The reported securities were included with the 571,428 shares of common stock purchased by HealthCare Ventures IX, L.P. for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock.

F1 · ownership.nature: The shares are owned directly by HealthCare Ventures IX, L.P. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HealthCare Partners IX, L.P. ("HCPIX"), which is the General Partner of HealthCare Ventures IX, L.P. Each of the HCVIX Directors, HCPIX LLC and HCPIX beneficially own and share voting and dispositive power with respect to all of the securities owned by HealthCare Ventures IX, L.P. Christopher Mirabelli disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.

SEC source: 0001104659-19-005836 · a4.xml · nonDerivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · CEO, President, Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,114,804

F1 · ownership.nature: The shares are owned directly by HealthCare Ventures IX, L.P. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HealthCare Partners IX, L.P. ("HCPIX"), which is the General Partner of HealthCare Ventures IX, L.P. Each of the HCVIX Directors, HCPIX LLC and HCPIX beneficially own and share voting and dispositive power with respect to all of the securities owned by HealthCare Ventures IX, L.P. Christopher Mirabelli disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.

SEC source: 0001104659-19-000513 · a4.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · Pres,CEO Chairman of Board · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2028-12-31

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 48 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of January 1, 2019, the Vesting Start Date.

SEC source: 0001104659-18-048862 · a4.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · CEO, President and COB · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 21,369

Underlying: Common Stock · 21,369 shares

Expires 2024-11-14

F1 · kind: Pro rata distribution from HealthCare Ventures IX, L.P. ("HCV IX") to its limited partner, Nine Capital Partners, LLC. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor are the Managing Members of Nine Capital Partners, LLC, and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC. Dr. Mirabelli disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.

F2 · kind: The reporting person is also (i) a Managing Director of HealthCare Partners IX, LLC, which is the General Partner of HealthCare Partners IX, L.P., which is the General Partner of HCV IX, (ii) a Managing Director of HealthCare Partners VIII, LLC, which is the General Partner of HealthCare Partners VIII, L.P., which is the General Partner of HealthCare Ventures VIII, L.P. ("HCV VIII"), and (iii) a Managing Director of HCV Strategic LLC, which is the General Partner of HealthCare Ventures Strategic Fund, L.P. ("HCV SF"). HCV IX continues to hold 3,573,376 shares of common stock, HCV VIII continues to hold 2,618,406 shares of common stock, and HCV SF continues to hold 343,889 shares of common stock, representing 24.3%, 17.8%, and 2.3%, respectively, and 44.5% in the aggregate, of the outstanding shares of common stock.

F1 · ownership.direct: Pro rata distribution from HealthCare Ventures IX, L.P. ("HCV IX") to its limited partner, Nine Capital Partners, LLC. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor are the Managing Members of Nine Capital Partners, LLC, and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC. Dr. Mirabelli disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.

F2 · ownership.direct: The reporting person is also (i) a Managing Director of HealthCare Partners IX, LLC, which is the General Partner of HealthCare Partners IX, L.P., which is the General Partner of HCV IX, (ii) a Managing Director of HealthCare Partners VIII, LLC, which is the General Partner of HealthCare Partners VIII, L.P., which is the General Partner of HealthCare Ventures VIII, L.P. ("HCV VIII"), and (iii) a Managing Director of HCV Strategic LLC, which is the General Partner of HealthCare Ventures Strategic Fund, L.P. ("HCV SF"). HCV IX continues to hold 3,573,376 shares of common stock, HCV VIII continues to hold 2,618,406 shares of common stock, and HCV SF continues to hold 343,889 shares of common stock, representing 24.3%, 17.8%, and 2.3%, respectively, and 44.5% in the aggregate, of the outstanding shares of common stock.

F1 · ownership.nature: Pro rata distribution from HealthCare Ventures IX, L.P. ("HCV IX") to its limited partner, Nine Capital Partners, LLC. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor are the Managing Members of Nine Capital Partners, LLC, and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC. Dr. Mirabelli disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.

F2 · ownership.nature: The reporting person is also (i) a Managing Director of HealthCare Partners IX, LLC, which is the General Partner of HealthCare Partners IX, L.P., which is the General Partner of HCV IX, (ii) a Managing Director of HealthCare Partners VIII, LLC, which is the General Partner of HealthCare Partners VIII, L.P., which is the General Partner of HealthCare Ventures VIII, L.P. ("HCV VIII"), and (iii) a Managing Director of HCV Strategic LLC, which is the General Partner of HealthCare Ventures Strategic Fund, L.P. ("HCV SF"). HCV IX continues to hold 3,573,376 shares of common stock, HCV VIII continues to hold 2,618,406 shares of common stock, and HCV SF continues to hold 343,889 shares of common stock, representing 24.3%, 17.8%, and 2.3%, respectively, and 44.5% in the aggregate, of the outstanding shares of common stock.

SEC source: 0001104659-18-025615 · a4.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · President, CEO & COB · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock, $0.001 par value per share · 50,000 shares

Expires 2028-04-17

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 48 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of April 18, 2018, the Vesting Start Date.

F1 · derivative.underlying_shares: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 48 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of April 18, 2018, the Vesting Start Date.

SEC source: 0001104659-17-069117 · a4.xml · derivative · entry 4

Mirabelli Christopher · CIK 0001262326 · Director · CEO, President, COB · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,057,769

Underlying: Common Stock, $0.001 par value per share · 1,057,769 shares

Expires 2024-11-14

F4 · price: The reported securities were included with the 1,057,759 shares of common stock purchased by HealthCare Ventures IX, L.P. for $6.085 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock.

F1 · ownership.nature: The shares are owned directly by HealthCare Ventures IX, L.P. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HealthCare Partners IX, L.P. ("HCPIX"), which is the General Partner of HealthCare Ventures IX, L.P. Each of the HCVIX Directors, HCPIX LLC and HCPIX beneficially own and share voting and dispositive power with respect to all of the securities owned by HealthCare Ventures IX, L.P. Christopher Mirabelli disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.

SEC source: 0001104659-17-069117 · a4.xml · nonDerivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · CEO, President, COB · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,573,376

F1 · ownership.nature: The shares are owned directly by HealthCare Ventures IX, L.P. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HealthCare Partners IX, L.P. ("HCPIX"), which is the General Partner of HealthCare Ventures IX, L.P. Each of the HCVIX Directors, HCPIX LLC and HCPIX beneficially own and share voting and dispositive power with respect to all of the securities owned by HealthCare Ventures IX, L.P. Christopher Mirabelli disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.

SEC source: 0001104659-17-003607 · a4.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · CEO,Pres,Chairman of the Board · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 330,303

Underlying: Common Stock, $0.001 par value per share · 330,303 shares

Expires 2027-01-22

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan and shall vest and become exercisable with respect to 33 1/3% of the Option Shares on the one-year anniversary of January 23, 2017, the Vesting Start Date (the "First Vesting Date"), after which it shall vest in a series of 24 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of the First Vesting Date.

F1 · derivative.underlying_shares: The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan and shall vest and become exercisable with respect to 33 1/3% of the Option Shares on the one-year anniversary of January 23, 2017, the Vesting Start Date (the "First Vesting Date"), after which it shall vest in a series of 24 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of the First Vesting Date.